home > about us > background
Simcyp Limited was founded in 2001 by Professor Geoff Tucker, Professor Amin Rostami-Hodjegan and Mr John Evans as a spin-out company from the University of Sheffield, UK. Early in 2012 Simcyp was acquired by Certara, a leading provider of drug discovery and development software and scientific consulting services. Simcyp operates as a stand-alone business unit within the Certara group which also includes Pharsight and Tripos.
Simcyp develops a user-friendly platform designed specifically to allow you to conduct simulations in representative virtual patient populations based on your in vitro and clinical data. The Simulator includes extensive demographic, physiologic and genomic databases which have allowed us to develop algorithms which account for patient variability. This enables the user to predict drug behaviour in the virtual patient population, as opposed to a virtual reference man, allowing individuals at extreme risk to be identified.
This pioneering work led to Professor Tucker and Professor Rostami-Hodjegan being jointly awarded the New Safer Medicines Faster Award 2004 by the European Federation for Pharmaceutical Sciences (EUFEPS). Simcyp Limited has since won several other awards including the Queen’s Award for Enterprise in Innovation in 2010.
The success of Simcyp is founded on the company maintaining the Simcyp Consortium. Members of the Consortium not only gain access to Simcyp’s Simulators and consultancy services, but are also able to guide the direction of the future development of the services which Simcyp offer. The Consortium includes leading pharmaceutical and biotechnology companies, Regulatory institutions and academic centres of excellence enjoy associate membership status. Simcyp is also supported by a world-renowned Scientific Advisory Board.
Simcyp is continuing to expand, developing long-term contacts with global pharmaceutical companies, academic institutes and regulatory authorities.